• Publications
  • Influence
Chondroitin for osteoarthritis.
BACKGROUND Osteoarthritis, a common joint disorder, is one of the leading causes of disability. Chondroitin has emerged as a new treatment. Previous meta-analyses have shown contradictory results onExpand
  • 122
  • 5
  • PDF
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
BACKGROUND Serious infections are a major concern for patients considering treatments for rheumatoid arthritis. Evidence is inconsistent as to whether biological drugs are associated with anExpand
  • 288
  • 4
  • PDF
Golimumab for Rheumatoid Arthritis: A Systematic Review
Objective. To perform a Cochrane systematic review of benefit (American College of Rheumatology 50% improvement criteria; ACR50) and safety (adverse events and withdrawals) of golimumab in patientsExpand
  • 26
  • 1
Golimumab for rheumatoid arthritis.
BACKGROUND Golimumab is a humanized inhibitor of Tumor necrosis factor-alpha, recently approved by the Food and Drug Administration (FDA) for the treatment of Rheumatoid arthritis (RA). OBJECTIVESExpand
  • 40
  • PDF
The Limits of Executive Authority to Preempt Contrary State Laws in Foreign Affairs after Medellín V. Texas
In 2012, the U.S. Court of Appeals for the Ninth Circuit decided Movsesian v. Victoria Versicherung AG after hearing the case three times. In the final hearing, the court held that an informalExpand
  • 1
Regional analgesia versus no regional analgesia for ambulatory hip arthroscopy in adults
Reason for withdrawal from publication April 2016 The authors of the protocol have decided not to continue with the review. The topic is not considered, at present, to be a priority topic and theExpand